Surgalign (NASDAQ:SRGA) updated its FY 2021 earnings guidance on Tuesday. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $107.10 million-112.20 million, compared to the consensus revenue estimate of $109.14 million.
Separately, Zacks Investment Research raised Surgalign from a sell rating to a hold rating in a research note on Wednesday, April 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Surgalign currently has an average rating of Buy and an average target price of $4.33.
Shares of NASDAQ SRGA traded down $0.01 during trading on Friday, hitting $1.47. The company had a trading volume of 40,136 shares, compared to its average volume of 1,785,393. The company has a 50 day simple moving average of $1.79. Surgalign has a 12 month low of $1.42 and a 12 month high of $3.97. The company has a market capitalization of $161.68 million, a price-to-earnings ratio of -5.69 and a beta of 2.14.
Surgalign Company Profile
Surgalign Holdings, Inc, a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for Surgalign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgalign and related companies with MarketBeat.com's FREE daily email newsletter.